Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NanoSight Acquired by Malvern Instruments

Published: Monday, September 30, 2013
Last Updated: Monday, September 30, 2013
Bookmark and Share
The acquisition of NanoSight by Malvern Instruments was completed on Friday 27 September.

NanoSight has developed and commercialized a unique and patented technology, Nanoparticle Tracking Analysis (NTA). The company's instrumentation and software enable the rapid and simultaneous multi-parameter analysis and characterization of many different types of nanoscale particles. With their ability to analyze particle size, concentration, zeta potential and aggregation, NanoSight systems are closely aligned with Malvern's market-leading Zetasizer range, extending Malvern's solutions for those working at the nanoscale. 

Currently the largest applications area for NTA is in life sciences, for the measurement of biological nanoparticles, where one of the most exciting and rapidly expanding fields is exosomes. These are intercellular messengers whose quantity and biochemical composition reflect the disease status of an individual. NanoSight technology uniquely provides quantitative detection and characterization capabilities to make exosomes a viable proposition as biomarkers for drug discovery, disease prognosis, diagnosis and monitoring as well as personalized medicine. 

Paul Walker, Managing Director of Malvern Instruments, said: "NanoSight is a real entrepreneurial success story and I am delighted to be welcoming the NanoSight team to Malvern. NanoSight has grown every year since it was established in 2002, achieving a turnover of £5.7 million in 2012, and has ambitious plans for the future. We will be providing the investment and support needed to continue this drive forward and are absolutely committed to developing the NanoSight brand within the Malvern portfolio. 

"NanoSight's unique technology has become accepted in laboratories around the world and is widely cited in research publications. With rapid advances in nanomaterials and the life sciences, in biopharmaceuticals especially, the demand for new technologies to answer continually evolving analytical challenges has never been greater. This is a very exciting time and by bringing together complementary, leading edge technologies, Malvern continues to focus on delivering the analytical tools which laboratories so urgently need." 

Jeremy Warren, CEO of NanoSight, said "We have always seen Malvern as clear leader in our sector, and the exemplar of what we wish to become. The plans we have are ambitious and exciting, and the support and reach of the Malvern organization will allow us to grow more rapidly than we could alone. I am sure that this change will bring opportunity to both our business and our colleagues. Malvern is our natural home." 

NanoSight employs around 50 people worldwide and will continue to operate from its current facilities in Amesbury, Wiltshire, UK, under the existing management team. Malvern's direct sales operations in key geographies and wider global presence will be used to make the NanoSight instruments and aftersales support even more accessible to a wider market.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Studying behaviour of Exosomes and Microvesicles using Nanoparticle Tracking Analysis
Dr Gregory Gores of the Mayo Clinic in Rochester, Minnesota is using NTA to study extracellular vesicles.
Tuesday, November 19, 2013
NanoSight Wins a 2013 Queen's Award for Enterprise – Innovation
Award follows on from their 2012 Queen's Award for Enterprise for International Trade.
Monday, April 22, 2013
Nanoparticle Tracking Analysis Technology Facilitates Cancer Metastasis Research
NanoSight reports on the breakthrough cancer metastasis research of Dr. Hector Peinado Selgas and Dr. David Lyden's research team from Weill Cornell Medical College.
Tuesday, November 13, 2012
Conference Highlights Biomarker Detection Role for NanoSight
Oxford researchers presented new data applying NTA to size and count both cellular microvesicles and exosomes at a low concentration.
Saturday, October 09, 2010
The Forschungszentrum Dresden-Rossendorf Chooses NanoSight to Characterize Magnetic Nanoparticles
NanoSight’s LM-20 nanoparticle characterization system to study magnetic nanoparticles for applications in cancer therapy.
Wednesday, August 18, 2010
NanoSight Holds First European Users Meeting on Nanoparticle Characterization in Langen, Germany
Meeting provided an excellent opportunity to present new data using nanoparticle tracking analysis, NTA.
Thursday, July 15, 2010
NanoSight holds first European users meeting on nanoparticle characterization in Langen, Germany
NanoSight, world-leading manufacturers of unique nanoparticle characterization technology, together with distributor partners Schaefer Technologie, have recently held a meeting of users of their successful range of nanoparticle tracking analysis instruments in Langen, Germany.
Tuesday, July 13, 2010
University of Leicester Uses NanoSight to Characterize Marine Viruses and Bacteriophages
Microbiologists use NanoSight system to study cyanobacteria and their viruses which involves the accurate enumeration of viral particles.
Wednesday, June 09, 2010
Leiden University uses NanoSight Characterization System to Aid their Drug Delivery Research Programs
NanoSight helps the research group to focus on vaccine delivery and on protein formulation and characterization with respect to immunogenicity.
Wednesday, February 24, 2010
Strathclyde’s Nanometrology Centre Selects NanoSight to Develop New Biosensors
University of Strathclyde has selected an LM-10 characterization system to aid in their research and development of new biosensors.
Wednesday, November 11, 2009
NanoSight to Supply Instrumentation for Wellcome Trust Technology Development Grant
NanoSight’s methodologies aimed at measuring cellular nanoparticles in plasma and urine as biomarkers of a broad range of human disease conditions.
Friday, May 22, 2009
NanoSight Nanoparticle Detection Technique Contributes to Virus Production to Counter MRSA
Researchers at the University of Strathclyde use virus particle detection and counting using Nanoparticle Tracking Analysis to combat MRSA.
Tuesday, December 09, 2008
NanoSight Receives £925,000 in Funding Round to Expand their Nanoparticle Characterization Business
The new round of financing which will enable the company to expand the business with the development of new products and sales channels in the US market.
Thursday, November 06, 2008
Nanosight Angel Investor Round
The angel investor round increases its shareholder base and complements previous investments by Venture Capital companies.
Monday, September 10, 2007
NanoSight Raises £250k in Second Tranche of Fundraising
The investment supports Company’s current sales drive and develops capabilities in nanoparticle analysis.
Wednesday, September 27, 2006
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Gene That Lowers Heart Attack Risk Identified
Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart disease.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Real-Time Imaging of Embryo Development Could Pave the Way
Researchers at IMCB have developed advanced microscopy technologies to monitor embryo development for more effective human reproduction therapies.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!